Homatropine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Homatropine
Accession Number
DB11181
Type
Small Molecule
Groups
Approved
Description

Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. In eye drops, homatropine is used as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil). It is also present in combination treatment HYCODAN along with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough; homatropine is included in a subtherapeutic amount as homatropine methylbromide to discourage deliberate overdosage.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Homatropine hydrobromideBEW7469QZ051-56-9DWSGTFTVBLXELC-RDYJJYPNSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Isopto Homatropine 2%Liquid2 %OphthalmicAlcon, Inc.1951-12-312016-04-14Canada
Isopto Homatropine 5%Liquid5 %OphthalmicAlcon, Inc.1951-12-312016-03-03Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Minims Homatropine Hydrobromide 2%Liquid2 %OphthalmicChauvin Pharmaceuticals Limited1995-12-312003-07-08Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HomatropineSolution / drops50 mg/5mLOphthalmicHub Pharmaceuticals2012-06-102016-02-20Us
Homatropine HydrobromideSolution50 mg/mLOphthalmicO Cu Soft, Inc.2014-02-10Not applicableUs
Homatropine Hydrobromide OphthalmicSolution50 mg/mLOphthalmicAltaire Pharmaceuticals Inc.2013-05-16Not applicableUs
Categories
UNII
8QS6WCL55Z
CAS number
87-00-3
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
ULiver carboxylesterase 1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Homatropine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumHomatropine may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Homatropine.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Homatropine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Homatropine is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Homatropine can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Homatropine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Homatropine.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Homatropine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Homatropine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Homatropine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Homatropine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Homatropine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Homatropine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Homatropine.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Homatropine.Experimental
Botulinum Toxin Type AHomatropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BHomatropine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Homatropine is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Homatropine.Approved, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Homatropine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Homatropine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Homatropine.Approved
CimetropiumHomatropine may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Homatropine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Homatropine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Homatropine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Homatropine.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Homatropine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Homatropine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Homatropine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Homatropine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Homatropine.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Homatropine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Homatropine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Homatropine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Homatropine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Homatropine is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Homatropine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Homatropine is combined with DPDPE.Experimental
DronabinolHomatropine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Homatropine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Homatropine can be decreased when used in combination with Edrophonium.Approved
EluxadolineHomatropine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Homatropine.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Homatropine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Homatropine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Homatropine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Homatropine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Homatropine.Approved
GalantamineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Homatropine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Homatropine.Approved
Ginkgo bilobaThe therapeutic efficacy of Homatropine can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Homatropine is combined with Glucagon recombinant.Approved
GlycopyrroniumHomatropine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Homatropine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Homatropine.Experimental
Huperzine AThe therapeutic efficacy of Homatropine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Homatropine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Homatropine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Homatropine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Homatropine.Approved
IpidacrineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Homatropine.Approved
IsoflurophateThe therapeutic efficacy of Homatropine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Homatropine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Ketobemidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Homatropine is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Homatropine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Homatropine can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Homatropine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Homatropine.Approved
MefloquineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Homatropine is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Homatropine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Homatropine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Homatropine.Approved, Investigational
MethscopolamineThe risk or severity of adverse effects can be increased when Homatropine is combined with Methscopolamine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Homatropine.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Homatropine is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Homatropine.Approved
MetoclopramideThe therapeutic efficacy of Homatropine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Homatropine.Approved
MianserinMianserin may increase the anticholinergic activities of Homatropine.Approved, Investigational
MinaprineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Homatropine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Morphine.Approved, Investigational
NabiloneHomatropine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Homatropine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Homatropine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Homatropine.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Homatropine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Homatropine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Homatropine.Approved
ParaoxonThe therapeutic efficacy of Homatropine can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Homatropine.Approved
PethidineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Homatropine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Homatropine.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Homatropine is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Homatropine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Homatropine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Homatropine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Homatropine.Approved
Potassium ChlorideHomatropine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Homatropine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Homatropine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Homatropine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Homatropine.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Homatropine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Homatropine.Approved
RamosetronHomatropine may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Homatropine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Homatropine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Sufentanil.Approved, Investigational
SulpirideHomatropine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TacrineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Homatropine is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Homatropine is combined with Tilidine.Experimental
TiotropiumHomatropine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Homatropine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Homatropine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Homatropine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Homatropine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Homatropine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Homatropine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Homatropine.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Homatropine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Homatropine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Homatropine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Homatropine.Approved
UmeclidiniumHomatropine may increase the anticholinergic activities of Umeclidinium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Homatropine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911146
ATC Codes
S01FA05 — Homatropine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic50 mg/5mL
SolutionOphthalmic50 mg/mL
LiquidOphthalmic5 %
LiquidOphthalmic2 %
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Bencharit S, Morton CL, Xue Y, Potter PM, Redinbo MR: Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol. 2003 May;10(5):349-56. [PubMed:12679808]

Drug created on December 03, 2015 09:51 / Updated on December 01, 2017 17:24